Impact of age and gender on the safety and efficacy of chemotherapy plus bevacizumab in metastatic colorectal cancer: a pooled analysis of TRIBE and TRIBE2 studies: Annals of oncology : official journal of the European Society for Medical Oncology

F Marmorino, D Rossini, S Lonardi, R Moretto, G Zucchelli, G Aprile, E Dell'Aquila, M Ratti, F Bergamo, G Masi, F Urbano, M Ronzoni, M Libertini, B Borelli, G Randon, A Buonadonna, G Allegrini, N Pella, V Ricci, A BoccaccinoTP Latiano, S Cordio, A Passardi, E Tamburini, L Boni, A Falcone, C Cremolini

Research output: Contribution to journalArticlepeer-review

Abstract

BACKGROUND: The phase III TRIBE and TRIBE2 studies randomized metastatic colorectal cancer patients to first-line FOLFOXIRI/bevacizumab or a doublet (FOLFIRI or FOLFOX)/bevacizumab. The studies demonstrated a significant benefit from the triplet at the price of an increased incidence of chemotherapy-related adverse events (AEs). In both trials, males and females aged between 18 and 70 years with ECOG PS ≤2 and between 71 and 75 years with ECOG PS = 0 were eligible. We investigated the effect of FOLFOXIRI/bevacizumab versus doublets/bevacizumab according to age and gender. PATIENTS AND METHODS: Subgroup analyses according to age (
Original languageEnglish
Pages (from-to)1969-1977
Number of pages9
JournalAnnals of Oncology
Volume30
Issue number12
DOIs
Publication statusPublished - 2019

Fingerprint

Dive into the research topics of 'Impact of age and gender on the safety and efficacy of chemotherapy plus bevacizumab in metastatic colorectal cancer: a pooled analysis of TRIBE and TRIBE2 studies: Annals of oncology : official journal of the European Society for Medical Oncology'. Together they form a unique fingerprint.

Cite this